Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 24,689,000 | 22,449,000 | 22,127,000 | 26,107,000 | 30,390,000 |
| Cost of Goods | 4,572,000 | 4,675,000 | 4,853,000 | 4,371,000 | 4,261,000 |
| Gross Profit | 20,117,000 | 17,774,000 | 17,274,000 | 21,736,000 | 26,129,000 |
| Operating Expenses | 16,046,000 | 13,487,000 | 9,074,000 | 7,612,000 | 8,496,000 |
| Operating Income | 4,071,000 | 4,287,000 | 8,200,000 | 14,124,000 | 17,633,000 |
| Interest Expense | 984,000 | 995,000 | 1,077,000 | 1,118,000 | 964,000 |
| Other Income | -1,418,000 | 1,868,000 | 676,000 | 523,000 | 428,000 |
| Pre-tax Income | 1,669,000 | 5,160,000 | 7,799,000 | 13,529,000 | 17,097,000 |
| Income Tax | 1,580,000 | -204,000 | 2,339,000 | 8,885,000 | 3,609,000 |
| Net Income Continuous | 89,000 | 5,364,000 | 5,460,000 | 4,644,000 | 13,488,000 |
| Minority Interests | -34,000 | -22,000 | 5,000 | 16,000 | -13,000 |
| Net Income | $123,000 | $5,386,000 | $5,455,000 | $4,628,000 | $13,501,000 |
| EPS Basic Total Ops | 0.10 | 4.24 | 4.20 | 3.54 | 10.08 |
| EPS Basic Continuous Ops | 0.07 | 4.22 | 4.21 | 3.55 | 10.07 |
| EPS Diluted Total Ops | 0.10 | 4.22 | 4.17 | 3.51 | 9.94 |
| EPS Diluted Continuous Ops | 0.07 | 4.20 | 4.17 | 3.52 | 9.93 |
| EPS Diluted Before Non-Recurring Items | 7.09 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $5,551,000 | $5,691,000 | $9,629,000 | $15,410,000 | $18,791,000 |